Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.

about

Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.

Item

http://www.wikidata.org/entity/Q41428337

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Systemic therapy for echinoder ...... lung cancer brain metastases.

@en

type

Item

label

Systemic therapy for echinoder ...... lung cancer brain metastases.

@en

prefLabel

Systemic therapy for echinoder ...... lung cancer brain metastases.

@en

P1476

Systemic therapy for echinoder ...... l lung cancer brain metastases

@en

P2093

Bo Lu

http://www.w3.org/2001/XMLSchema#string

Jenny Guo

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

Wei Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.

P304

E1028-E1031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2016.09.09

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas G Zaorsky

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27747054

http://www.w3.org/2001/XMLSchema#string

P932

5059245

http://www.w3.org/2001/XMLSchema#string